|Dr. William K. Heiden||CEO, Pres & Director||1.67M||N/A||1960|
|Mr. Edward H. Myles||Exec. VP, CFO & Treasurer||791.49k||N/A||1972|
|Dr. Julie Krop||Exec. VP of Devel. & Chief Medical Officer||787.94k||N/A||1966|
|Mr. James Alan Butcher||Exec. VP & Chief Bus. Officer||841.97k||N/A||1967|
|Ms. Linda S. Lennox||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company's products candidates include Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women; AMAG-423, a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent for the treatment of oral anticoagulants or low molecular weight heparin. It sells Feraheme to authorized wholesalers and specialty distributors. The company has a license agreement with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio LLC, Perosphere Pharmaceuticals Inc., Antares Pharma, Inc., and Abeona Therapeutics, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
AMAG Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 2. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 1; Compensation: 3.